| 70.98 0 (0%) | 11-14 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 82.9 | 1-year : | 96.83 |
| Resists | First : | 70.98 | Second : | 82.9 |
| Pivot price | 70.45 |
|||
| Supports | First : | 70.34 | Second : | 69.95 |
| MAs | MA(5) : | 70.67 |
MA(20) : | 70.41 |
| MA(100) : | 69.11 |
MA(250) : | 67.11 |
|
| MACD | MACD : | 0.2 |
Signal : | 0.2 |
| %K %D | K(14,3) : | 87.4 |
D(3) : | 76.4 |
| RSI | RSI(14): 79.3 | |||
| 52-week | High : | 70.98 | Low : | 55.09 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ AXNX ] has closed Bollinger Bands are 7.3% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 71.08 - 71.44 | 71.44 - 71.74 |
| Low: | 70.14 - 70.52 | 70.52 - 70.84 |
| Close: | 70.42 - 71.02 | 71.02 - 71.51 |
Axonics, Inc., a medical technology company, engages in the development and commercialization of sacral neuromodulation (SNM) systems. The company's SNM systems are used to treat patients with overactive bladder, including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence and non-obstructive urinary retention. Its proprietary rechargeable SNM System (r-SNM) delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of bladder and bowel dysfunction. The company also offers Bulkamid, a urethral bulking agent to treat female stress urinary incontinence. It sells its products through a direct salesforce and distributors in the United States, the United Kingdom, Germany, the Netherlands, Nordic countries, and internationally. The company was formerly known as Axonics Modulation Technologies, Inc. and changed its name to Axonics, Inc. in March 2021. Axonics, Inc. was incorporated in 2012 and is based in Irvine, California.
Mon, 18 Nov 2024
Boston Scientific Closes Acquisition of Axonics - FinSMEs
Fri, 15 Nov 2024
Boston Scientific Completes $3.7B Axonics Acquisition, Expands Urology Portfolio - Stock Titan
Fri, 15 Nov 2024
Boston Scientific finalizes $3.7B acquisition of Axonics - MassDevice
Fri, 15 Nov 2024
Boston Scientific Closes Acquisition of Axonics, Inc. - PR Newswire
Thu, 07 Nov 2024
Axonics Modulation Technologies (AXNX) Q3 Earnings and Revenues Top Estimates - Yahoo Finance
Thu, 07 Nov 2024
Axonics Reports Third Quarter 2024 Financial Results - BioSpace
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 51 (M) |
| Shares Float | 50 (M) |
| Held by Insiders | 1.2 (%) |
| Held by Institutions | 87.2 (%) |
| Shares Short | 3,310 (K) |
| Shares Short P.Month | 3,600 (K) |
| EPS | -0.11 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 13 |
| Profit Margin | -1.4 % |
| Operating Margin | -2.5 % |
| Return on Assets (ttm) | -0.7 % |
| Return on Equity (ttm) | -0.9 % |
| Qtrly Rev. Growth | 24.7 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 8.45 |
| EBITDA (p.s.) | 0.1 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 14 (M) |
| Levered Free Cash Flow | 17 (M) |
| PE Ratio | -709.81 |
| PEG Ratio | 0 |
| Price to Book value | 5.46 |
| Price to Sales | 8.39 |
| Price to Cash Flow | 253.86 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|